WO2009071697A1 - Hydrogel cohésif monophasique biodégradable - Google Patents
Hydrogel cohésif monophasique biodégradable Download PDFInfo
- Publication number
- WO2009071697A1 WO2009071697A1 PCT/EP2008/067029 EP2008067029W WO2009071697A1 WO 2009071697 A1 WO2009071697 A1 WO 2009071697A1 EP 2008067029 W EP2008067029 W EP 2008067029W WO 2009071697 A1 WO2009071697 A1 WO 2009071697A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crosslinking
- gel
- polymers
- hydrogel according
- hydrogel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/738—Cross-linked polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/594—Mixtures of polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Definitions
- the invention relates to the field of cross-linked biodegradable hydrogels having applications in aesthetics, for example or in medicine.
- aesthetic applications include the filling of fine lines, wrinkles and skin defects and the increase in volumes.
- Examples of medical applications include periurethral injection for the treatment of urinary incontinence by sphincter insufficiency, post-surgical injection to prevent peritoneal adhesions in particular; injection for replacement of deficient biological fluids (in the joints especially to replace the deficient synovial fluid), and injection following surgery of scleral laser scleral presbyopia.
- hydrogels used must have optimized properties in terms of in vivo remanence, rheology and in terms of viscosity to ensure good "injectability," these hydrogels being applied by injection using needles of varying sizes. depending on the application, but which must be as thin as possible in order to minimize postinjection reactions.
- compositions based on permanent or very slowly biodegradable particles dispersed in an injection vector for example PMMA particles.
- biodegradable implants based on cross-linked or non-cross-linked polysaccharides, essentially based on sodium hyaluronate.
- IPN Interpenetrating Polymer Network
- Si IPN semiinterpenetrated polymer networks
- compositions which comprise a continuous phase and a dispersed phase consisting of insoluble fragments of a hydrogel.
- the aqueous continuous phase serves as a vehicle for injecting fragments of the dispersed phase.
- the present invention makes it possible to solve these various disadvantages.
- the present invention consists of a biodegradable monophasic cohesive hydrogel characterized in that it consists of a homogeneous mixture of x identical or different polymers, crosslinked prior to their interpenetration by mixing, in the form of a monophasic hydrogel, said crosslinked polymers being insoluble in water and miscible with each other and x being between 2 and 5.
- the cohesiveness and monophasic nature of a gel according to the invention means the property of said gel to maintain its stability and its unity without the possibility of separating the constituent gels.
- Such a product has the advantages of IPN networks without the disadvantages of implementation thereof and allows through the use of a different degree of crosslinking for each constituent gel (or the same if the gels have very different molecular weights ) to create more or less dense networks before their final hydration and after mixing to obtain a product whose rheological properties can be "adjusted” by measuring the properties of the various constituent gels before mixing.
- the crosslinking reactions can thus be carried out on isolated polymers, thus avoiding the problems of selectivity.
- the implementation is thus easy and allows to meet the final requirements while using natural products whose properties, including molecular weight, may vary from one batch to another.
- the implementation of the crosslinking conditions is simple, each gel being crosslinked independently of one another.
- the mixture thus obtained will combine the advantages of each of the different constituent gels by minimizing their disadvantages without causing the side effects observed with the use of the particulate compositions. Optimization and synergy will be observed in the resulting properties both in terms of injectivity and in terms of remanence.
- the synergy is obtained because of the optimization of the two parameters which act reciprocally on one another, the low crosslinking promoting the injectability and disadvantageous afterglow and strong crosslinking promoting persistence and contrario disadvantageous injectability.
- the respective properties of the networks complement each other, so that the highest elastic parameter freeze will induce an increase in the elastic parameter of the assembly in comparison with the least crosslinked gel.
- the lowest level of injectability level gel will reduce the level of injectability of the whole.
- a hydrogel by its constitution, will have a degradation kinetics depending on the number of mixed gels and crosslinking rates. Indeed, the kinetics of degradation is a function of several parameters: the degree of crosslinking, the polymer concentration and the molecular weight of the polymers used at the time of crosslinking.
- the kinetics of degradation will be slowed down: in fact, homogeneous mixing of gels of variable degrees of remanence will make it possible to reinforce the overall remanence by a "dilution" effect of the random cuts of the gel by means of either free radicals or enzymes. (hyaluronidases, etc.) present in the dermis or the biological fluid replaced.
- the finished product thus manufactured will be more remanent for equivalent levels of injectability, while remaining perfectly biodegradable.
- the hydrogel according to the invention is characterized in that the polymers are chosen from polysaccharides.
- the hydrogel according to the invention is characterized in that the polymers are chosen from the group consisting of polylactic acids and their derivatives, N-vinyl pyrrolidone, polyvinyl acids, polyacrylamides and acrylic polymers and biologically acceptable derivatives.
- the polysaccharides are chosen from the group consisting of hyaluronic acid, keratane, heparin, cellulose and cellulose derivatives, alginic acid, xanthan, carrageenan, chitosan, chondroitin and their biologically acceptable salts. .
- At least one of the x polysaccharides is selected from the group consisting of hyaluronic acid and its biologically acceptable salts.
- the hydrogel according to the invention is characterized in that at least one of the x polysaccharides is chosen from the group consisting of cellulose derivatives and their biologically acceptable salts.
- the hydrogel according to the invention is characterized in that at least one of the x polysaccharides is chosen from the group consisting of chondroitin and its biologically acceptable salts.
- the hydrogel according to the invention is characterized in that at least one of the x polysaccharides is chosen from group consisting of chitosan and its salts and biologically acceptable derivatives.
- the polysaccharides that can be used in the hydrogel according to the present invention are of any type known in the art and are preferably chosen from those produced by bacterial fermentation. Generally, the polysaccharides that may be used in the context of the present invention have a molecular weight MW of between about 0.02 and about 6 MDa, preferably between about 0.04 and about 4 MDa, more preferably between about 0.05 and about 3 MDa.
- Hyaluronic acid and its salts, in particular its physiologically acceptable salts, such as the sodium, potassium and calcium salts, advantageously the sodium salt, are particularly preferred.
- chondroitin sulfate and its salts and cellulose derivatives such as hydroxypropylmethylcellulose or carboxymethylcellulose and mixtures of two or more of them.
- the gels constituting the hydrogel according to the invention are preferably based on sodium hyaluronate.
- the x polymers are the same.
- the x polymers are different.
- the hydrogel according to the invention is characterized in that x is equal to 2.
- the first of the x polysaccharides is chosen from the group consisting of hyaluronic acid and its salts, cellulose derivatives and their salts and xanthan and the second is selected from the group consisting of chondroitin sulfate and its salts, chitosan and its salts and derivatives, cellulose derivatives and their salts and alginic acids.
- the first of the x polymers is selected from the group consisting of hyaluronic acid and its salts, cellulose derivatives and their salts and xanthan and the second is selected from the group consisting of polylactics and their derivatives and acrylic derivatives.
- the first of the x polymers is selected from the group of sodium hyaluronate and the second is selected from the group consisting of chondroitin sulfate and its salts, chitosan and its salts and derivatives, cellulose derivatives and their salts and alginic acids.
- the weight ratio between the highly crosslinked polysaccharide and the weakly crosslinked polysaccharide can vary in very large proportions, depending on the nature of the polysaccharides used, their respective levels of crosslinking, and also according to the final properties referred to .
- the proportion by weight of the highly crosslinked polysaccharide gel in the finished product is between about 0.1 and 99.9%, preferably from 5 to 50% of gel 1 having a degree of crosslinking x1 and from 50 to 95% of gel 2 having a degree of crosslinking x2 or even more preferably from 10 to 40% of gel 1 having a degree of crosslinking x1 and from 60 to 90% of gel 2 having a degree of crosslinking x2.
- the invention also relates to the process for preparing a biodegradable hydrogel according to the invention; this method comprises a step of development of a specification setting the rheological properties targeted according to the applications. For the determination of the degree of remanence, elasticity is targeted, this resulting from the degree of crosslinking and for the determination of the injectability, the high shear rate viscosity also related to the degree of crosslinking is fixed, these parameters depend on the products. starting point, in particular their molecular mass.
- the process for preparing a biodegradable monophasic cohesive hydrogel according to the invention is characterized in that it comprises at least the steps of: crosslinking a first polymer to a degree of crosslinking x1 - crosslinking of a second polymer at a crosslinking rate x2 interpenetration by intimate mixing of the two polymers, hydration final interpenetration by final mixing after hydration.
- the hydration is carried out for example by immersion in or addition of a buffered isotonic solution.
- the method further comprises x steps for crosslinking the polymers before mixing the crosslinked polymers.
- the hydration is generally carried out in an aqueous medium, by simply mixing the mixture of crosslinked gels with an aqueous solution, advantageously physiological buffer, so as to obtain a final concentration, variable in very large proportions, depending on the nature of the polysaccharides used, their respective levels of crosslinking, and also according to the intended use.
- the buffered solution that can be used may for example be a physiological, osmolar solution having a pH of between about 6.8 and about 7.5.
- This final concentration of total polysaccharides is generally from about 5 to about 100 mg / g, preferably from about 5 to about 50 mg / g, for example about 20 mg / g of hydrogel.
- the method of the present invention thus makes it possible to obtain a monophasic cohesive hydrogel that is biodegradable, injectable and has a long remanence.
- the two crosslinking steps are carried out in a medium whose pH value is identical or different.
- Each of these steps can be carried out in an acidic or basic medium, preferably in a basic medium, for example at a pH of between 8 and 14, preferably between 8 and 13.
- crosslinking reactions used in the process of the invention are reactions well known to those skilled in the art.
- those skilled in the art can develop and optimize the crosslinking conditions according to said polysaccharide and said crosslinking agent: crosslinking rate, temperature, pH. It is however specified that the crosslinking steps are carried out at a constant pH, either acidic or basic, as indicated above.
- the crosslinking agents which are involved in the crosslinking steps are generally bi- or poly-functional crosslinking agents of different types, and may for example be chosen from DVS (divinylsulfone) in an alkaline medium. (see US 4,582,865), bi- or poly-functional epoxies (see US 4,716,154), carbodi-imides, formaldehyde (see GB 2,151,244).
- bi- or poly-epoxide type agents the reactions being carried out in a basic medium to generate ether linkages with the -OH functions of the polysaccharide, or in an acidic medium, which gives rise to ester-type bonds.
- the patent application WO 2000/46253 successively uses these two pH conditions in order to optimize the crosslinking of the polysaccharide.
- it is preferred to carry out the crosslinking reactions under basic pH conditions since, in aqueous medium, the ester bonds, obtained in an acid medium, are generally more labile than the ether bonds obtained in basic medium.
- crosslinking agent it is possible to use an epoxide or its derivatives, and especially 1,4-butanedioldiglycidyl ether (BDDE), diepoxyoctane or 1,2-bis (2,3-epoxypropyl) -2, 3-ethylene. It is most preferred to use 1,4-butanedioldiglycidyl ether (BDDE) for each of the crosslinking steps.
- BDDE 1,4-butanedioldiglycidyl ether
- each of the crosslinking steps may be carried out with one or more crosslinking agents, which may be the same or different in one or other of the steps, under the pH conditions indicated above.
- the polysaccharides may advantageously be purified, according to standard purification techniques (for example by continuous water flow washing, dialysis baths, and the like), in order to eliminate the residual crosslinking agent. not reacting.
- crosslinking steps may advantageously be followed by a neutralization step (i.e. up to a pH value of about 7), for example by adding a suitable amount of 1N hydrochloric acid.
- a neutralization step i.e. up to a pH value of about 7
- the polymers have different levels of crosslinking, at least one of the x polymers having a degree of crosslinking x1 and at least one of the x polymers having a degree of crosslinking x2 and xl being higher. at x2.
- the polymers have identical levels of crosslinking. It being understood that the polymers may have different molecular weights. In one embodiment x1 and x2 are between 0.02 and 0.4 and preferably between 0.08 and 0.2.
- the crosslinking it may be advantageous to neutralize the gel obtained, according to standard methods known in the art, and for example by adding acid when the crosslinking is carried out in a basic medium, and by adding a base, when the crosslinking is conducted in acidic medium.
- the mixture obtained at the end of the process may optionally be subjected to a complementary hydration step, in order to obtain a gel in the form of an injectable hydrogel, adapted to the envisaged applications.
- the invention relates to the use of a hydrogel according to the invention for the formulation of a viscosupplementation composition.
- the invention relates to the use of a hydrogel according to the invention for the formulation of a composition for filling wrinkles.
- the targeted applications are more particularly the applications commonly observed in the context of injectable viscoelastic polysaccharides used or potentially usable in the following pathologies or treatments:
- the hydrogel according to the invention may be used:
- the hydrogel according to the invention also has an important application in joint surgery and dental surgery for filling periodontal pockets, for example.
- hydrogel according to the present invention being more widely intended to: fill volumes;
- the hydrogel according to the invention can also find a very interesting application as a release matrix of one or more active principle (s) previously dispersed therein.
- active ingredient is meant any pharmacologically active product: active drug ingredient, antioxidant (sorbitol, mannitol ...), antiseptic, anti-inflammatory, local anesthetics (lidocaine ...) etc.
- the hydrogel according to the invention preferably after purification and hydration in hydrogel, can be packaged, for example in syringes, and sterilized according to any means known per se (for example by autoclaving) for marketing and / or direct use.
- the present invention relates to a kit comprising a hydrogel according to the invention, packaged in a sterile syringe.
- Sodium hyaluronate fibers of injectable quality (1 g, molecular weight: about 2.7 MDa); are weighed in a container. An aqueous solution of 1% sodium hydroxide in water (7.4 g) is added, the whole is homogenized for about 1 hour with a spatula, at room temperature and
- BDDE (65 mg) is added to the uncrosslinked sodium hyaluronate (NaHA) gel obtained in the previous step, the whole being homogenized with a spatula for about 30 minutes at room temperature.
- the assembly is then placed in a water bath at 50 ° C. for 2 h 20 in order to obtain an X 1 crosslinking rate of approximately 0.14.
- the final crosslinked gel is then neutralized by addition of 1N HCl, and placed in a phosphate buffer bath to stabilize the pH and allow its hydration, or swelling up to 30 mg / g of HA .
- a cross-linked NaHa hydrogel is thus obtained by the conventionally used route: G1 with a HA concentration of approximately 30 mg / g.
- One part of the gel is kept at this concentration, the other is diluted by addition of phosphate buffer to obtain 20 mg / g of HA in the end, this gel is then homogenized before being filled into syringes which are sterilized by autoclaving: syringes of gel G1 at 20 mg / g sterile.
- Crosslinking Gel 2
- Sodium hyaluronate fibers of injectable quality (1 g, molecular weight: about 1.5 MDa); are weighed and previously dried in a container.
- An aqueous solution of 1% sodium hydroxide in water (6.3 g) is added, the whole is homogenized for about 1 hour with a spatula, at room temperature and 900 mm Hg.
- BDDE 43 mg is added to the uncrosslinked sodium hyaluronate gel (NaHA) obtained in the preceding step, the whole being homogenized with a spatula, at room temperature and atmospheric pressure for approximately 30 minutes.
- the assembly is then placed in a water bath at 50O for 2 h 20 in order to obtain an X 2 crosslinking rate of approximately 0.09.
- crosslinked final gel is then neutralized by addition of 1N HCl, and placed in a phosphate buffer bath to stabilize the pH and allow its hydration, or swelling up to 30 mg / g of HA.
- a cross-linked NaHa hydrogel is thus obtained by the conventionally used route: G2 concentration of HA about 30 mg / g.
- the mixture thus obtained is a gel homogeneous at 20 mg / g HA, composed of 2 interpenetrating networks, this gel is then packaged in syringes and autoclaved.
- the half-life times of the interpenetrated gel networks obtained according to the invention are longer, guaranteeing a longer in vivo persistence time.
- the "biphasic" type product after centrifugation shows particles decanted at the bottom of the syringe. If we eject the product of the syringe, the viscous comes out first, then the particles that have no cohesiveness between them, agglomerated in the bottom of the syringe, and make the injectability particularly difficult.
- the extrusion force is characterized on Mecmesin traction bench under compression speed 50 mm / min with 23G1% needles, the results are given in the table below.
- the elasticity is characterized on TA Instruments AR 2000 Ex rheometer, oscillating at 25 °, the value of the elasticity being recorded at a frequency of 1 Hz, the results are given in the table below.
- This step is identical to step b) of synthesis of gel 1 of Example 1, with 81 mg of BDDE.
- a gel 3 of crosslinking rate X3 of about 0.17 is obtained.
- Step c) Neutralization, purification This step is identical to step c) of synthesis of Gel 1 of Example 1, to obtain a gel G3 with a HA concentration of about 30 mg / g.
- the mixture thus obtained is a homogeneous gel at 24 mg / g HA, composed of 2 interpenetrating networks, this gel is then packaged in syringes and autoclaved.
- the homogenization conditions are the same as in Example 1.
- One part of the gel is kept at this concentration, the other is diluted by adding phosphate buffer to obtain 24 mg / g of HA in the end, this gel is then homogenized before being filled into syringes which are sterilized by autoclaving: syringes of G5 gel at 24 mg / g sterile.
- step c) of Example 1 Same as step c) of Example 1 with 41 mg of BDDE. The whole is brought to the water bath at 50O for 3 hours, to obtain a degree of crosslinking X6 of about 0.09.
- step c) of synthesis of the preceding gel to obtain a gel 6 to 30 mg / g.
- One part of the gel is kept at this concentration, the other is diluted by adding phosphate buffer to obtain 24 mg / g of HA in the end, this gel is then homogenized before being filled in syringes which are sterilized by autoclaving: syringes of G6 gel at 24 mg / g sterile.
- Interpenetration of gels 4, 5 and 6 (respective proportions: 25%, 5%, 70%) 5 g of G4 gel at 30 mg / g are weighed, 1 g of G5 gel at 30 mg / g and then 14 g of G6 gel at 30 mg / g.
- the gel G7 composed of the interpenetration of the 3 crosslinked gels (G4, G5 and G6) has the lowest extrusion force, this for an elasticity value about 20% higher than that of the G6 level gel. injectability close but slightly higher.
- crosslinked final gel is then neutralized by addition of 1N HCl, and placed in a phosphate buffer bath to stabilize the pH and allow its hydration, or swelling up to 45 mg / g of HA.
- a cross-linked CMC Na hydrogel is thus obtained by the conventionally used route: G8 with a CMC concentration approximately
- the gel G1 of HA crosslinked at a rate of 0.14, at a concentration of 30 mg / g is added in various proportions to the crosslinked CMC Na G8 gel, phosphate buffer is added to adjust the final concentrations to 26 mg / g in HA and 37 mg / g in CMC, the 2 gels are placed under slow mechanical stirring with the phosphate buffer for 1 hour under hyperbaric pressure. 3 interpenetrating gels are thus obtained as described below: Gel 9: 30% G1 + 70% G8
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Surgery (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Polymers & Plastics (AREA)
- Prostheses (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08858227.5A EP2231108B1 (fr) | 2007-12-07 | 2008-12-08 | Hydrogel cohésif monophasique biodégradable |
ES08858227.5T ES2538999T3 (es) | 2007-12-07 | 2008-12-08 | Hidrogel cohesivo monofásico biodegradable |
MX2010006248A MX2010006248A (es) | 2007-12-07 | 2008-12-08 | Hidrogel cohesivo monofasico biodegradable. |
JP2010536490A JP5571562B2 (ja) | 2007-12-07 | 2008-12-08 | 生分解性の単一相結着性親水ゲル |
CA2708023A CA2708023C (fr) | 2007-12-07 | 2008-12-08 | Hydrogel cohesif monophasique biodegradable |
CN2008801256588A CN101925348B (zh) | 2007-12-07 | 2008-12-08 | 可生物降解的单相粘性水凝胶 |
PL08858227T PL2231108T3 (pl) | 2007-12-07 | 2008-12-08 | Biodegradowalny jednofazowy spójny hydrożel |
AU2008333132A AU2008333132B2 (en) | 2007-12-07 | 2008-12-08 | Biodegradable single-phase cohesive hydrogel |
BRPI0821046A BRPI0821046B1 (pt) | 2007-12-07 | 2008-12-08 | hidrogel coesivo monofásico biodegradável, processo de preparação do mesmo, utilização de um hidrogel, e, kit |
EA201070696A EA022478B1 (ru) | 2007-12-07 | 2008-12-08 | Когезионный однофазный биоразлагаемый гидрогель, способ его получения и применение |
US12/746,639 US20100303873A1 (en) | 2007-12-07 | 2008-12-08 | Biodegradable single-phase cohesive hydrogels |
IL206166A IL206166A (en) | 2007-12-07 | 2010-06-03 | One-phase biodegradable hydrogel gel |
HK11104897.3A HK1150772A1 (en) | 2007-12-07 | 2011-05-17 | Biodegradable single-phase cohesive hydrogel |
US14/164,592 US9919076B2 (en) | 2007-12-07 | 2014-01-27 | Biodegradable single-phase cohesive hydrogels |
US15/812,588 US10207024B2 (en) | 2007-12-07 | 2017-11-14 | Biodegradable single-phase cohesive hydrogels |
US16/249,606 US20190167844A1 (en) | 2007-12-07 | 2019-01-16 | Biodegradable single-phase cohesive hydrogels |
US17/364,081 US20210322636A1 (en) | 2007-12-07 | 2021-06-30 | Biodegradable single-phase cohesive hydrogels |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0759641A FR2924615B1 (fr) | 2007-12-07 | 2007-12-07 | Hydrogel cohesif biodegradable. |
FR0759641 | 2007-12-07 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/746,639 A-371-Of-International US7993350B2 (en) | 2004-10-04 | 2007-05-09 | Shapeable or steerable guide sheaths and methods for making and using them |
US12/746,639 A-371-Of-International US20100303873A1 (en) | 2007-12-07 | 2008-12-08 | Biodegradable single-phase cohesive hydrogels |
US14/164,592 Continuation US9919076B2 (en) | 2007-12-07 | 2014-01-27 | Biodegradable single-phase cohesive hydrogels |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009071697A1 true WO2009071697A1 (fr) | 2009-06-11 |
Family
ID=39473297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/067029 WO2009071697A1 (fr) | 2007-12-07 | 2008-12-08 | Hydrogel cohésif monophasique biodégradable |
Country Status (18)
Country | Link |
---|---|
US (5) | US20100303873A1 (fr) |
EP (2) | EP2231108B1 (fr) |
JP (2) | JP5571562B2 (fr) |
KR (1) | KR101597333B1 (fr) |
CN (1) | CN101925348B (fr) |
AU (1) | AU2008333132B2 (fr) |
BR (1) | BRPI0821046B1 (fr) |
CA (1) | CA2708023C (fr) |
EA (1) | EA022478B1 (fr) |
ES (2) | ES2538999T3 (fr) |
FR (1) | FR2924615B1 (fr) |
HK (1) | HK1150772A1 (fr) |
IL (1) | IL206166A (fr) |
MX (1) | MX2010006248A (fr) |
PL (2) | PL2231108T3 (fr) |
PT (2) | PT2231108E (fr) |
UA (1) | UA99161C2 (fr) |
WO (1) | WO2009071697A1 (fr) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012508217A (ja) * | 2008-11-07 | 2012-04-05 | アンタイス エス.エイ. | ヒアルロン酸又はその塩の1種、ポリオール及びリドカインの熱滅菌された注射用組成物 |
FR2968305A1 (fr) * | 2010-12-06 | 2012-06-08 | Teoxane | Procede de preparation d'un gel reticule |
JP2013502941A (ja) * | 2009-08-27 | 2013-01-31 | フィディア ファーマチェウティチ ソシエタ ペル アチオニ | 新規な充填剤としての粘弾性ゲル |
FR3006689A1 (fr) * | 2013-06-11 | 2014-12-12 | Benedicte Vincente Tauzin | Procede de reticulation de l'acide hyaluronique; procede de preparation d'un hydrogel injectable; hydrogel obtenu; utilisation de l'hydroget obtenu |
WO2014198406A1 (fr) * | 2013-06-11 | 2014-12-18 | Anteis S.A. | Procédé de réticulation de l'acide hyaluronique, procédé de préparation d'un hydrogel injectable, hydrogel obtenu et utilisation de l'hydrogel obtenu |
US9155757B2 (en) | 2013-10-07 | 2015-10-13 | Laboratoires Vivacy | Methods and kits for treating vaginal and vulvar vestibule mucosa disorders |
US9314530B2 (en) | 2012-06-13 | 2016-04-19 | Laboratoires Vivacy | Composition, in aqueous medium, that comprises at least a hyaluronic acid and at least an hydrosoluble salt of sucrose octasulfate |
EP3040117A1 (fr) * | 2014-12-29 | 2016-07-06 | Galderma S.A. | Hydrogels de sulfate de chondroïtine réticulée par éther et leur utilisation pour des applications de tissu mou |
EP3040118A1 (fr) * | 2014-12-29 | 2016-07-06 | Galderma S.A. | Hydrogels de chondroïtine réticulée d'éther et leur utilisation pour des applications de tissu mou |
US9402799B2 (en) | 2012-08-29 | 2016-08-02 | Laboratories Vivacy | Sterilized composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate |
WO2016180904A1 (fr) | 2015-05-11 | 2016-11-17 | Laboratoires Vivacy | Compositions comprenant au moins un polyol et au moins un anesthesique |
WO2016207496A1 (fr) | 2015-06-24 | 2016-12-29 | Tauzin Bénédicte Vincente | Procede de preparation d'un hydrogel reticule injectable; hydrogel obtenu; utilisation de l'hydrogel obtenu |
EP3173086A1 (fr) | 2013-12-23 | 2017-05-31 | Laboratoires Vivacy | Compositions d'acide hyaluronique comprenant de la mépivacaïne |
WO2017098091A1 (fr) | 2015-12-07 | 2017-06-15 | Tauzin Bénédicte Vincente | Nouvelle composition injectable; procede de preparation de ladite composition; utilisation de ladite composition |
WO2017102001A1 (fr) | 2015-12-16 | 2017-06-22 | Vplus International Sa | Composition d'acide hyaluronique pour injections peniennes |
WO2017140958A1 (fr) | 2016-02-15 | 2017-08-24 | Tauzin Bénédicte Vincente | Composition injectable; procédé de préparation de ladite composition; utilisation de ladite composition |
EP3315130A1 (fr) | 2016-10-28 | 2018-05-02 | Laboratoires Vivacy | Composition a base d'acide hyaluronique comprenant de la mepivacaïne |
US10004824B2 (en) | 2015-05-11 | 2018-06-26 | Laboratoires Vivacy | Compositions comprising at least one polyol and at least one anesthetic |
WO2018220283A1 (fr) | 2017-05-29 | 2018-12-06 | Kh Medtech Sarl | Composition injectable sterile contenant de l'acide hyaluronique reticule et de l'articaine |
EP3125961B1 (fr) | 2014-04-01 | 2019-07-31 | Merz Pharma GmbH & Co. KGaA | Produits de comblement de tissu mou à base de polysaccharide, à persistance améliorée |
WO2020095079A1 (fr) * | 2018-11-06 | 2020-05-14 | Kylane Laboratoires Sa | Composition injectable contenant de l'acide hyaluronique pour des applications au niveau du corps |
WO2020212615A1 (fr) | 2019-04-17 | 2020-10-22 | Laboratoires Vivacy | Procede de reticulation d'un polymere |
WO2021260145A1 (fr) | 2020-06-24 | 2021-12-30 | Laboratoires Vivacy | Procede d'incorporation de composes organiques en solution au sein d'un hydrogel |
WO2022038156A1 (fr) | 2020-08-20 | 2022-02-24 | Laboratoires Vivacy | Procede d'evaluation des caracteristiques rheologiques d'un gel |
WO2023187131A1 (fr) | 2022-03-30 | 2023-10-05 | Laboratoires Vivacy | Emulsion comprenant un hydrogel et de la graisse ou un derive de graisse |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2861734B1 (fr) | 2003-04-10 | 2006-04-14 | Corneal Ind | Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus |
CA2687990A1 (fr) | 2007-05-23 | 2008-12-04 | Allergan, Inc. | Collagene reticule et utilisations de ce dernier |
US8318695B2 (en) | 2007-07-30 | 2012-11-27 | Allergan, Inc. | Tunably crosslinked polysaccharide compositions |
US8697044B2 (en) | 2007-10-09 | 2014-04-15 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
SI2818184T1 (sl) | 2007-11-16 | 2019-03-29 | Aclaris Therapeutics, Inc. | Sestava in postopki za zdravljenje purpure |
US8394784B2 (en) | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having multi-stage bioactive agent delivery |
US8394782B2 (en) | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
US8450475B2 (en) | 2008-08-04 | 2013-05-28 | Allergan, Inc. | Hyaluronic acid-based gels including lidocaine |
JP5722217B2 (ja) | 2008-09-02 | 2015-05-20 | アラーガン・ホールディングス・フランス・ソシエテ・パール・アクシオン・サンプリフィエAllergan Holdings France S.A.S. | ヒアルロン酸および/またはその誘導体の糸、その作製方法、ならびにその使用 |
US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
US20110172180A1 (en) | 2010-01-13 | 2011-07-14 | Allergan Industrie. Sas | Heat stable hyaluronic acid compositions for dermatological use |
CA2792729C (fr) | 2010-03-12 | 2016-06-28 | Allergan Industrie, Sas | Composition fluide pour l'amelioration d'etats cutanes |
CA2794254C (fr) | 2010-03-22 | 2018-09-04 | Allergan, Inc. | Hydrogels reticules a base de polysaccharides et de proteines- polysaccharides pour l'augmentation des tissus mous |
US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US9005605B2 (en) | 2010-08-19 | 2015-04-14 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8883139B2 (en) | 2010-08-19 | 2014-11-11 | Allergan Inc. | Compositions and soft tissue replacement methods |
WO2012022478A2 (fr) * | 2010-08-19 | 2012-02-23 | Merz Pharma Gmbh & Co. Kgaa | Composition d'agent de remplissage comprenant des bêta-glucanes |
US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US20130096081A1 (en) | 2011-06-03 | 2013-04-18 | Allergan, Inc. | Dermal filler compositions |
US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
CN103702659B (zh) | 2011-06-03 | 2016-12-21 | 阿勒根公司 | 包括抗氧化剂的皮肤填充剂组合物 |
US20130244943A1 (en) | 2011-09-06 | 2013-09-19 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US9662422B2 (en) | 2011-09-06 | 2017-05-30 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
SG11201408312UA (en) | 2012-06-15 | 2015-01-29 | Merz Pharma Gmbh & Co Kgaa | Method of preparing a composition based on hyaluronic acid |
KR101421933B1 (ko) * | 2012-06-19 | 2014-07-28 | 서울과학기술대학교 산학협력단 | 생분해성 하이브리드 하이드로젤 및 그 제조방법 |
WO2015026423A1 (fr) | 2013-08-20 | 2015-02-26 | Infusion Medical, Inc. | Système de remplissage de seringue et procédé associé |
USD774182S1 (en) | 2014-06-06 | 2016-12-13 | Anutra Medical, Inc. | Anesthetic delivery device |
USD763433S1 (en) | 2014-06-06 | 2016-08-09 | Anutra Medical, Inc. | Delivery system cassette |
USD750768S1 (en) | 2014-06-06 | 2016-03-01 | Anutra Medical, Inc. | Fluid administration syringe |
CN104086788B (zh) * | 2014-07-17 | 2016-08-17 | 华熙福瑞达生物医药有限公司 | 一种注射用修饰透明质酸钠凝胶 |
US10722444B2 (en) | 2014-09-30 | 2020-07-28 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
TWI716365B (zh) * | 2014-11-13 | 2021-01-21 | 德商梅茲製藥有限兩合公司 | 注射型真皮填充劑組合物及其套組、製備方法、與使用 |
WO2016128783A1 (fr) | 2015-02-09 | 2016-08-18 | Allergan Industrie Sas | Compositions et méthodes pour améliorer l'apparence de la peau |
CN104771331B (zh) * | 2015-03-12 | 2017-12-12 | 华熙福瑞达生物医药有限公司 | 一种透明质酸弹性体及其应用 |
US10722443B2 (en) | 2016-09-14 | 2020-07-28 | Rodan & Fields, Llc | Moisturizing compositions and uses thereof |
AU2017218138B2 (en) | 2016-02-12 | 2022-04-07 | Rodan & Fields, Llc | Moisturizing compositions and uses thereof |
KR101710639B1 (ko) * | 2016-06-07 | 2017-03-08 | 주식회사 파마리서치프로덕트 | 핵산, 키토산 및 히알루론산을 포함하는 조직 증강용 충전 조성물 및 이의 제조방법 |
US10018133B2 (en) | 2016-09-22 | 2018-07-10 | Ford Global Technologies, Llc | System and method to extend operating time of valve actuators of an internal combustion engine |
JP6939607B2 (ja) * | 2017-03-27 | 2021-09-22 | Jsr株式会社 | 組成物およびその用途 |
CN108250462A (zh) * | 2017-05-08 | 2018-07-06 | 上海利康瑞生物工程有限公司 | 一种抗酶解交联透明质酸钠凝胶及其制备方法和制剂 |
KR101944008B1 (ko) * | 2017-09-18 | 2019-01-30 | (주) 제이씨바이오 | 히알루론산을 포함하는 투명 하이드로겔 막 및 이를 이용한 콘택트렌즈 |
FR3072026B1 (fr) * | 2017-10-10 | 2019-10-25 | Capsum | Ensembles de particules, procedes de preparation et kits les comprenant |
WO2019195256A1 (fr) | 2018-04-04 | 2019-10-10 | Board Of Regents, The University Of Texas System | Hydrogels élastiques biodégradables pour bio-impression |
JP7248967B2 (ja) * | 2018-04-23 | 2023-03-30 | 国立大学法人北海道大学 | ハイドロゲル及びハイドロゲルの製造方法 |
LU101045B1 (en) | 2018-12-11 | 2020-06-11 | Qventis GmbH | Method for the manufacture and use of a bionic hydrogel composition for medical applications |
CN111249172A (zh) * | 2020-01-15 | 2020-06-09 | 陈勇 | 一种美容注射凝胶及其制备方法 |
EP3854377A1 (fr) * | 2020-01-22 | 2021-07-28 | Laboratoires Genevrier Sas | Composition comprenant de l'acide hyaluronique et un polyol ou de carboxyméthylcellulose |
US20230321319A1 (en) * | 2020-08-18 | 2023-10-12 | Innate S.R.L. | Injectable composition and use of said composition |
WO2023064618A1 (fr) * | 2021-10-15 | 2023-04-20 | Prohibix Llc | Précipités d'acide hyaluronique réticulé |
WO2023107199A1 (fr) | 2021-12-09 | 2023-06-15 | L'oreal | Compositions cosmétiques correctrices de peau et leurs méthodes d'utilisation |
FR3130132B1 (fr) | 2021-12-09 | 2023-11-17 | Oreal | Dispersion comprenant une particule polymerique, un agent stabilisant a groupe cycloalkyle, une huile, et de l’eau, procede de traitement des matieres keratiniques mettant en œuvre la dispersion |
FR3132220B1 (fr) | 2022-01-31 | 2024-02-02 | Oreal | compositions cosmétiques perfectrices de peau et procédés d’utilisation |
FR3130131B1 (fr) | 2021-12-09 | 2023-11-17 | Oreal | Dispersion comprenant une particule polymerique, un agent stabilisant a groupe cycloalkyle, une huile, et un polyol, procede de traitement des matieres keratiniques mettant en œuvre la dispersion |
CN116444826A (zh) * | 2023-06-05 | 2023-07-18 | 天新福(北京)医疗器材股份有限公司 | 一种交联改性胶原蛋白凝胶、其制备方法和凝胶产品 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2733427A1 (fr) * | 1995-04-25 | 1996-10-31 | W K Et Associes | Compositions biphasiques injectables renfermant de l'acide hyaluronique, notamment utiles en chirurgies reparatrice et esthetique |
WO2005061611A1 (fr) * | 2003-12-23 | 2005-07-07 | Hyaltech Limited | Compositions a reseau de polymeres semi-interpenetrants |
FR2865737A1 (fr) * | 2004-02-03 | 2005-08-05 | Anteis Sa | Gel reticule biocompatible |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1238043A (fr) | 1983-12-15 | 1988-06-14 | Endre A. Balazs | Preparations d'acide hyaluronique insolubles dans l'eau et procede de production |
SE442820B (sv) | 1984-06-08 | 1986-02-03 | Pharmacia Ab | Gel av tverbunden hyaluronsyra for anvendning som glaskroppssubstitut |
US4582865A (en) | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US5143724A (en) | 1990-07-09 | 1992-09-01 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
IT1260154B (it) * | 1992-07-03 | 1996-03-28 | Lanfranco Callegaro | Acido ialuronico e suoi derivati in polimeri interpenetranti (ipn) |
FR2733426B1 (fr) | 1995-04-25 | 1997-07-18 | Debacker Yves | Dispositif medical pour le comblement des deformations du volume de la peau telles que rides et cicatrices par injection de 2 formes physico-chimiques differentes d'un polymere biologique |
JP3538741B2 (ja) * | 1995-05-23 | 2004-06-14 | 独立行政法人 科学技術振興機構 | 複合刺激応答型生体内分解性高分子ヒドロゲル |
US6224893B1 (en) * | 1997-04-11 | 2001-05-01 | Massachusetts Institute Of Technology | Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering |
AU752800B2 (en) | 1997-07-03 | 2002-10-03 | Depuy Acromed, Inc. | Cross-linked polysaccharide drug carrier |
FR2780730B1 (fr) * | 1998-07-01 | 2000-10-13 | Corneal Ind | Compositions biphasiques injectables, notamment utiles en chirurgies reparatrice et esthetique |
GB9902412D0 (en) | 1999-02-03 | 1999-03-24 | Fermentech Med Ltd | Process |
FR2811996B1 (fr) * | 2000-07-19 | 2003-08-08 | Corneal Ind | Reticulation de polysaccharide(s), preparation d'hydrogel(s) ; polysaccharide(s) et hydrogel(s) obtenus,leurs utilisations |
WO2003093327A1 (fr) | 2002-05-01 | 2003-11-13 | Hokkaido Technology Licensing Office Co., Ltd. | Gel ayant une structure multiple en réseau et procédé de production |
US7334043B2 (en) * | 2002-09-17 | 2008-02-19 | At&T Delaware Intellectual Property, Inc. | Extending functionality of workflow applications using instant messaging (IM) |
FR2861734B1 (fr) | 2003-04-10 | 2006-04-14 | Corneal Ind | Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus |
US8293890B2 (en) * | 2004-04-30 | 2012-10-23 | Advanced Cardiovascular Systems, Inc. | Hyaluronic acid based copolymers |
US20050281880A1 (en) * | 2004-05-20 | 2005-12-22 | Wei Wang | Methods for making injectable polymer hydrogels |
WO2006013612A1 (fr) | 2004-06-18 | 2006-02-09 | Hokkaido Technology Licensing Office Co., Ltd. | Ménisque articulaire artificiel du genou |
JP2006013612A (ja) * | 2004-06-22 | 2006-01-12 | Traffic Shimu:Kk | データ監視システム、プログラム、記録媒体、表示操作方法 |
US20060105022A1 (en) * | 2004-11-15 | 2006-05-18 | Shiseido Co., Ltd. | Process for preparing crosslinked hyaluronic acid gel |
CN1302050C (zh) * | 2005-07-07 | 2007-02-28 | 复旦大学 | 一种互穿网络聚合物超多孔水凝胶及其制备方法和应用 |
AU2006289625B2 (en) * | 2005-09-09 | 2013-08-29 | Ottawa Health Research Institute | Interpenetrating networks, and related methods and compositions |
WO2007041627A1 (fr) * | 2005-10-03 | 2007-04-12 | Pinsky Mark A | Préparations et méthodes pour soin de la peau amélioré |
-
2007
- 2007-12-07 FR FR0759641A patent/FR2924615B1/fr not_active Expired - Fee Related
-
2008
- 2008-12-08 BR BRPI0821046A patent/BRPI0821046B1/pt active IP Right Grant
- 2008-12-08 WO PCT/EP2008/067029 patent/WO2009071697A1/fr active Application Filing
- 2008-12-08 EP EP08858227.5A patent/EP2231108B1/fr active Active
- 2008-12-08 AU AU2008333132A patent/AU2008333132B2/en active Active
- 2008-12-08 PT PT88582275T patent/PT2231108E/pt unknown
- 2008-12-08 KR KR1020107014771A patent/KR101597333B1/ko active IP Right Grant
- 2008-12-08 EP EP12196144.5A patent/EP2572702B1/fr active Active
- 2008-12-08 CA CA2708023A patent/CA2708023C/fr active Active
- 2008-12-08 UA UAA201008468A patent/UA99161C2/ru unknown
- 2008-12-08 PL PL08858227T patent/PL2231108T3/pl unknown
- 2008-12-08 US US12/746,639 patent/US20100303873A1/en not_active Abandoned
- 2008-12-08 ES ES08858227.5T patent/ES2538999T3/es active Active
- 2008-12-08 MX MX2010006248A patent/MX2010006248A/es active IP Right Grant
- 2008-12-08 PL PL12196144T patent/PL2572702T3/pl unknown
- 2008-12-08 ES ES12196144.5T patent/ES2526081T3/es active Active
- 2008-12-08 EA EA201070696A patent/EA022478B1/ru not_active IP Right Cessation
- 2008-12-08 CN CN2008801256588A patent/CN101925348B/zh active Active
- 2008-12-08 JP JP2010536490A patent/JP5571562B2/ja active Active
- 2008-12-08 PT PT121961445T patent/PT2572702E/pt unknown
-
2010
- 2010-06-03 IL IL206166A patent/IL206166A/en active IP Right Grant
-
2011
- 2011-05-17 HK HK11104897.3A patent/HK1150772A1/xx unknown
-
2014
- 2014-01-27 US US14/164,592 patent/US9919076B2/en active Active
- 2014-06-25 JP JP2014130602A patent/JP5883076B2/ja active Active
-
2017
- 2017-11-14 US US15/812,588 patent/US10207024B2/en active Active
-
2019
- 2019-01-16 US US16/249,606 patent/US20190167844A1/en not_active Abandoned
-
2021
- 2021-06-30 US US17/364,081 patent/US20210322636A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2733427A1 (fr) * | 1995-04-25 | 1996-10-31 | W K Et Associes | Compositions biphasiques injectables renfermant de l'acide hyaluronique, notamment utiles en chirurgies reparatrice et esthetique |
WO2005061611A1 (fr) * | 2003-12-23 | 2005-07-07 | Hyaltech Limited | Compositions a reseau de polymeres semi-interpenetrants |
FR2865737A1 (fr) * | 2004-02-03 | 2005-08-05 | Anteis Sa | Gel reticule biocompatible |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012508217A (ja) * | 2008-11-07 | 2012-04-05 | アンタイス エス.エイ. | ヒアルロン酸又はその塩の1種、ポリオール及びリドカインの熱滅菌された注射用組成物 |
EP2349203B2 (fr) † | 2008-11-07 | 2020-02-26 | Anteis S.A. | Composition injectable a base d'acide hyaluronique ou l'un de ses sels, de polyols et de lidocaïne, sterilisée à la chaleur |
EP2676658B1 (fr) | 2008-11-07 | 2015-09-16 | Anteis SA | Composition injectable à base d'acide hyaluronique, de polyol(s) et de lidocaïne, stérilisée à la chaleur |
JP2013502941A (ja) * | 2009-08-27 | 2013-01-31 | フィディア ファーマチェウティチ ソシエタ ペル アチオニ | 新規な充填剤としての粘弾性ゲル |
FR2968305A1 (fr) * | 2010-12-06 | 2012-06-08 | Teoxane | Procede de preparation d'un gel reticule |
WO2012077054A1 (fr) * | 2010-12-06 | 2012-06-14 | Teoxane | Procédé de préparation d'un gel réticulé |
US9393189B2 (en) | 2010-12-06 | 2016-07-19 | Teoxane | Process of preparing a crosslinked gel |
RU2590558C2 (ru) * | 2010-12-06 | 2016-07-10 | Теоксан | Способ получения поперечно-сшитого геля |
US9314530B2 (en) | 2012-06-13 | 2016-04-19 | Laboratoires Vivacy | Composition, in aqueous medium, that comprises at least a hyaluronic acid and at least an hydrosoluble salt of sucrose octasulfate |
EP3797757A1 (fr) | 2012-08-29 | 2021-03-31 | Laboratoires Vivacy | Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium |
US9402799B2 (en) | 2012-08-29 | 2016-08-02 | Laboratories Vivacy | Sterilized composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate |
US10058499B2 (en) | 2012-08-29 | 2018-08-28 | Laboratoires Vivacy | Sterilized composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate |
FR3006689A1 (fr) * | 2013-06-11 | 2014-12-12 | Benedicte Vincente Tauzin | Procede de reticulation de l'acide hyaluronique; procede de preparation d'un hydrogel injectable; hydrogel obtenu; utilisation de l'hydroget obtenu |
CN105358186A (zh) * | 2013-06-11 | 2016-02-24 | 安特易斯有限公司 | 交联透明质酸的方法,制备可注射水凝胶的方法,得到的水凝胶,得到的水凝胶的用途 |
WO2014198406A1 (fr) * | 2013-06-11 | 2014-12-18 | Anteis S.A. | Procédé de réticulation de l'acide hyaluronique, procédé de préparation d'un hydrogel injectable, hydrogel obtenu et utilisation de l'hydrogel obtenu |
EP3007737B1 (fr) | 2013-06-11 | 2017-10-18 | Anteis SA | Procédé de réticulation de l'acide hyaluronique, procédé de préparation d'un hydrogel injectable, hydrogel obtenu et utilisation de l'hydrogel obtenu |
US9782490B2 (en) | 2013-06-11 | 2017-10-10 | Anteis S.A. | Method for crosslinking hyaluronic acid; method for preparing an injectable hydrogel; hydrogel obtained; use of the obtained hydrogel |
WO2014199022A1 (fr) * | 2013-06-11 | 2014-12-18 | Tauzin Bénédicte Vincente | Procede de reticulation de l'acide hyaluronique; procede de preparation d'un hydrogel injectable; hydrogel obtenu; utilisation de l'hydrogel obtenu |
US9155757B2 (en) | 2013-10-07 | 2015-10-13 | Laboratoires Vivacy | Methods and kits for treating vaginal and vulvar vestibule mucosa disorders |
EP3173086A1 (fr) | 2013-12-23 | 2017-05-31 | Laboratoires Vivacy | Compositions d'acide hyaluronique comprenant de la mépivacaïne |
EP3125961B1 (fr) | 2014-04-01 | 2019-07-31 | Merz Pharma GmbH & Co. KGaA | Produits de comblement de tissu mou à base de polysaccharide, à persistance améliorée |
EP3040118A1 (fr) * | 2014-12-29 | 2016-07-06 | Galderma S.A. | Hydrogels de chondroïtine réticulée d'éther et leur utilisation pour des applications de tissu mou |
EP3040117A1 (fr) * | 2014-12-29 | 2016-07-06 | Galderma S.A. | Hydrogels de sulfate de chondroïtine réticulée par éther et leur utilisation pour des applications de tissu mou |
WO2016180904A1 (fr) | 2015-05-11 | 2016-11-17 | Laboratoires Vivacy | Compositions comprenant au moins un polyol et au moins un anesthesique |
US10004824B2 (en) | 2015-05-11 | 2018-06-26 | Laboratoires Vivacy | Compositions comprising at least one polyol and at least one anesthetic |
US10588922B2 (en) | 2015-06-24 | 2020-03-17 | Kylane Laboratoires Sa | Method for preparing an injectable cross-linked hydrogel, hydrogel obtained; and use of the obtained hydrogel |
WO2016207496A1 (fr) | 2015-06-24 | 2016-12-29 | Tauzin Bénédicte Vincente | Procede de preparation d'un hydrogel reticule injectable; hydrogel obtenu; utilisation de l'hydrogel obtenu |
US10500225B2 (en) | 2015-12-07 | 2019-12-10 | Kh Medtech Sárl | Injectable composition; method for preparing said composition; use of said composition |
WO2017098091A1 (fr) | 2015-12-07 | 2017-06-15 | Tauzin Bénédicte Vincente | Nouvelle composition injectable; procede de preparation de ladite composition; utilisation de ladite composition |
WO2017102001A1 (fr) | 2015-12-16 | 2017-06-22 | Vplus International Sa | Composition d'acide hyaluronique pour injections peniennes |
WO2017140958A1 (fr) | 2016-02-15 | 2017-08-24 | Tauzin Bénédicte Vincente | Composition injectable; procédé de préparation de ladite composition; utilisation de ladite composition |
EP3315130A1 (fr) | 2016-10-28 | 2018-05-02 | Laboratoires Vivacy | Composition a base d'acide hyaluronique comprenant de la mepivacaïne |
WO2018220283A1 (fr) | 2017-05-29 | 2018-12-06 | Kh Medtech Sarl | Composition injectable sterile contenant de l'acide hyaluronique reticule et de l'articaine |
WO2018220288A1 (fr) | 2017-05-29 | 2018-12-06 | Tauzin Benedicte Vincente | Composition injectable stérile contenant de l'acide hyaluronique réticule et de l'articaine |
WO2020095079A1 (fr) * | 2018-11-06 | 2020-05-14 | Kylane Laboratoires Sa | Composition injectable contenant de l'acide hyaluronique pour des applications au niveau du corps |
WO2020212615A1 (fr) | 2019-04-17 | 2020-10-22 | Laboratoires Vivacy | Procede de reticulation d'un polymere |
FR3095206A1 (fr) | 2019-04-17 | 2020-10-23 | Laboratoires Vivacy | Procede de reticulation d’un polymere |
WO2021260145A1 (fr) | 2020-06-24 | 2021-12-30 | Laboratoires Vivacy | Procede d'incorporation de composes organiques en solution au sein d'un hydrogel |
FR3111903A1 (fr) | 2020-06-24 | 2021-12-31 | Laboratoires Vivacy | Procede d’incorporation de composes organiques en solution au sein d’un hydrogel |
WO2022038156A1 (fr) | 2020-08-20 | 2022-02-24 | Laboratoires Vivacy | Procede d'evaluation des caracteristiques rheologiques d'un gel |
FR3113522A1 (fr) | 2020-08-20 | 2022-02-25 | Laboratoires Vivacy | procédé d’évaluation des caractéristiques rhéologiques d’un gel |
WO2023187131A1 (fr) | 2022-03-30 | 2023-10-05 | Laboratoires Vivacy | Emulsion comprenant un hydrogel et de la graisse ou un derive de graisse |
FR3135399A1 (fr) | 2022-03-30 | 2023-11-17 | Laboratoires Vivacy | émulsion comprenant un hydrogel et de la graisse ou un dérivé de graisse |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2572702B1 (fr) | Hydrogel cohésif monophasique biodégradable | |
EP2011816B1 (fr) | Gel co-réticulé de polysaccharides | |
EP2785745B1 (fr) | Procédé de substitution et réticulation simultanées d'un polysaccharide via ses fonctions hydroxyles | |
WO2014199022A1 (fr) | Procede de reticulation de l'acide hyaluronique; procede de preparation d'un hydrogel injectable; hydrogel obtenu; utilisation de l'hydrogel obtenu | |
CA2534033A1 (fr) | Matrice complexe a usage biomedical | |
WO1996033751A1 (fr) | Compositions biphasiques injectables renfermant de l'acide hyaluronique, notamment utiles en chirurgies reparatrice et esthetique | |
EP2349203A2 (fr) | Composition injectable a base d'acide hyaluronique ou l'un de ses sels, de polyols et de lidocaïne, sterilisee a la chaleur | |
CA2985695A1 (fr) | Compositions comprenant au moins un polyol et au moins un anesthesique | |
FR3035327A1 (fr) | Solution aqueuse homogene de chitosane ou derive de chitosane injectable presentant un ph proche du ph physiologique | |
CA3040778A1 (fr) | Nouvelles compositions actives sur les adipocytes | |
EP3956386A1 (fr) | Procede de reticulation d'un polymere | |
WO2023079154A1 (fr) | Composition, sous forme de solution aqueuse comprenant au moins un compose macromoleculaire | |
WO2023198917A1 (fr) | Hydrogels pour le comblement des tissus mous | |
FR2794763A1 (fr) | Nouveaux derives de l'acide hyaluronique, leur preparation et leur utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880125658.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08858227 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010536490 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2708023 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2010/006248 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008333132 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008858227 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2008333132 Country of ref document: AU Date of ref document: 20081208 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20107014771 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201070696 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201008468 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12746639 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: PI0821046 Country of ref document: BR Free format text: IDENTIFIQUE E COMPROVE QUE O SIGNATARIO DA PETICAO NO 020100050437 DE 07/06/2010 TEM PODERES PARA ATUAR EM NOME DO DEPOSITANTE, UMA VEZ QUE BASEADO NO ARTIGO 216 DA LEI 9.279/1996 DE 14/05/1996 (LPI) "OS ATOS PREVISTOS NESTA LEI SERAO PRATICADOS PELAS PARTES OU POR SEUS PROCURADORES, DEVIDAMENTE QUALIFICADOS.". |
|
ENP | Entry into the national phase |
Ref document number: PI0821046 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100607 |